Zura Bio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Dianthus Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Evommune 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Nuvig Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Kyverna Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Cabaletta Bio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Cartesian Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Arcutis Biotherapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Black Diamond Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Prelude Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Foghorn Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Chronic Kidney Disease Indication Strategy Report 2026: SGLT2, MR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.